|
|
Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus |
Ji Min Kim,1 Sorim Choung,2 Kyong Hye Joung,1 Ju Hee Lee,1 Hyun Jin Kim,1 and Bon Jeong Ku 1 |
1Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. |
2Department of Medical Science, Chungnam National University School of Medicine, Daejeon, Korea. |
Corresponding author: Bon Jeong Ku. Department of Internal Medicine, Chungnam National University School of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea. Email: bonjeong@cnu.ac.kr
|
|
Received November 22, 2017; Accepted February 02, 2018.
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
|
Abstract
|
We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum sEGFR was positively correlated with glycosylated hemoglobin and serum glucose and negatively correlated with serum insulin and C-peptide levels.
|
|
|
Keywords:
Biological assay; Diabetes mellitus, type 2; Receptor, epidermal growth factor
|
|